Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $1.0 million.

  • Oncology Institute's Share-based Compensation fell 5713.69% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 6755.85%. This contributed to the annual value of $11.2 million for FY2024, which is 3738.35% down from last year.
  • As of Q3 2025, Oncology Institute's Share-based Compensation stood at $1.0 million, which was down 5713.69% from $752000.0 recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Share-based Compensation peaked at $24.4 million during Q4 2021, and registered a low of $42000.0 during Q1 2021.
  • In the last 5 years, Oncology Institute's Share-based Compensation had a median value of $4.1 million in 2023 and averaged $4.4 million.
  • In the last 5 years, Oncology Institute's Share-based Compensation skyrocketed by 2026428.57% in 2022 and then plummeted by 7779.75% in 2025.
  • Oncology Institute's Share-based Compensation (Quarter) stood at $24.4 million in 2021, then plummeted by 75.11% to $6.1 million in 2022, then plummeted by 32.8% to $4.1 million in 2023, then tumbled by 68.4% to $1.3 million in 2024, then decreased by 20.56% to $1.0 million in 2025.
  • Its Share-based Compensation was $1.0 million in Q3 2025, compared to $752000.0 in Q2 2025 and $1.5 million in Q1 2025.